Directed new share issue in Biotec Pharmacon ASA (NO) — NOK 78 million

Carnegie acted as sole book-runner in the directed new share issue of 3.9 million new shares at a subscription price of NOK 20 per share. Biotec Pharmacon develops, manufactures and markets immune modulating compounds for the human health sectors and marine enzymes used in molecular biology.April 2014.